NCT03856658Active, not recruitingPhase 2
Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases
A Phase II Trial of Hepatic Artery Infusional Floxuridine With Systemic Chemotherapy in the Treatment of Pancreatic Cancer Liver Metastases
Source: ClinicalTrials.gov · Last updated 16 Jul 2026
Brief summary (registry, in English)
This is a single arm, phase II study without blinding. The purpose is to determine the impact of hepatic artery infusion Floxuridine (FUDR) on liver metastases from pancreatic adenocarcinoma. Patients at Spectrum Health will receive standard of care chemotherapy. They will also receive chemotherapy via surgically placed hepatic artery infusion (HAI) pump.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- First submitted
- 25 Feb 2019
- Start date
- 5 Feb 2019
- Primary completion date
- Dec 2028
- Lead sponsor
- Corewell Health West
- NCT number
- NCT03856658
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 14
- From 5 Feb 2019 to the primary completion date, Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Model for End Stage Liver Disease (MELD) score \>20, using the variables of: Bilirubin, serum Sodium, International Normalized Ratio (INR), serum Creatinine, and Dialysis twice in the past week.
Other
- Primary tumor resected
- Greater than 60% liver parenchymal involvement by tumor
- Evidence of peritoneal metastases
- Current alcohol abuse
- Pregnant or lactating women
Who the study is looking for
- Biopsy-proved pancreatic adenocarcinoma with synchronous liver metastases
- Elevated Cancer Antigen 19-9 (CA19-9) at diagnosis (\>37 U/mL)
- Ages 18-75 years
- Karnofsky performance status ≥70
- Ability to undergo general anesthesia and HAI pump placement procedure
- CT or MRI scan imaging of the abdomen demonstrating accessibility of the gastroduodenal artery within 2 months of enrollment
- Received a minimum of 2 months of systemic chemotherapy with stable tumor markers and imaging.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Corewell Health West Coordinator of this site? Confirm its status | Grand Rapids | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.